Skip to content
News Articles
-
Strategia Therapeutics makes major paradigm shift in new drug R&D
-
Strategia starts phase I of Fujifilm cancer candidate
-
Strategia Therapeutics licensed in E6201 from Eisai, Japan: Dr. Keizo Koya, CEO and President of Strategia Therapeutics, truly wants to rescue promising shelved drug candidates to transform into valuable drugs for patients in need
-
Win-Win-Win for patients
-
TAPBOOST® – Breakthrough Technology to Improve Protein Production
-
Boston Strategics In-licensed E6201, a dual kinase inhibitor, from Eisai to Initiate Their Own Phase 2a Clinical Trial in 2014
-
Pioneering pharmaceutical R&D paradigm to provide affordable drugs available more quickly for patients
-
Special Interview with Keizo Koya, CEO and Eita Kitayama, President of Boston Strategics Corporation
-
Dr. Keizo Koya, CEO of Boston Strategics Corp., develops an innovative pharmaceutical R&D paradigm with “True” Open Innovation® platform
-
How Japan can Leverage Structural Changes in US Pharmaceutical Industry – Interview with Co-Founders of Boston Strategics
-
COMPANY TO WATCH: Boston Strategics (Boston, US) to Produce Drug R&D for Providing Global Support for Japanese Companies – Alliance with a World Class Cancer Center
-
Strategic Alliance with MD Anderson – Drug Development Support for Japanese companies